A detailed history of Bio Impact Capital LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 503,398 shares of XENE stock, worth $20.5 Million. This represents 3.66% of its overall portfolio holdings.

Number of Shares
503,398
Previous 323,398 55.66%
Holding current value
$20.5 Million
Previous $10.1 Million 99.67%
% of portfolio
3.66%
Previous 1.98%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$30.3 - $40.15 $5.45 Million - $7.23 Million
180,000 Added 55.66%
503,398 $20.2 Million
Q2 2025

Aug 14, 2025

BUY
$28.23 - $38.37 $564,600 - $767,400
20,000 Added 6.59%
323,398 $10.1 Million
Q1 2025

May 15, 2025

BUY
$33.55 - $40.74 $3.56 Million - $4.33 Million
106,186 Added 53.84%
303,398 $10.2 Million
Q4 2024

Feb 14, 2025

BUY
$38.14 - $45.74 $1.2 Million - $1.44 Million
31,412 Added 18.95%
197,212 $7.73 Million
Q3 2024

Nov 12, 2024

BUY
$36.12 - $43.96 $5.99 Million - $7.29 Million
165,800 New
165,800 $6.52 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.54B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.